English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Obstetric antiphospholipid antibody syndrome (OAPS) is associated with adverse pregnancy outcomes. A systematic review (2004) demonstrated diversity in published studies, making it difficult to interpret the outcomes in various subgroups with OAPS. Clinicians (and patients) are divided about the efficacy of any treatment, given the heterogeneity of the patient populations studied, endpoints, outcome measures reported and treatments used. Many of these patients are being cared for by their rheumatologist, haematologist, obstetrician and fertility specialists – who may have different recommendations concerning the need for lowmolecular weight heparin (LMWH). Women who have sought fertility treatment are finding it difficult to discontinue their LMWH despite the lack of evidence for its efficacy. The lack of consensus on therapeutic measures between various clinical specialities and patients often leads to poor patient experience. Patient involvement in the decision making process in these studies have not been reported; it could be the prime motivation for clinicians to continue prescribing LMWH despite the lack of demonstrable efficacy. Hence we need to develop a core outcome set so that clinicians from various subspecialities and patients will be able to assess each of these studies in a standardised fashion.

The urgent need for a multi-disciplinary core outcome set for the reporting of obstetric antiphospholipid antibody syndrome